ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic AR-C155858 During Fixed Treadmill Exercise in MPTP Mice: An Exploratory Study.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative movement disorder of high global burden. Uncertainties regarding its exact etiology have been hindering the development of curative therapies. As microglia, the brain's immune cells, are suspected to contribute to neurodegeneration by instigating neuroinflammation, existing anti-inflammatory agents could potentially serve as disease-modifying treatments for PD. Here we evaluated the impact of montelukast, a leukotriene receptor antagonist and anti-inflammatory drug, on motor symptoms and neuropathology in an α-synuclein transgenic mouse model (Line 61) for early onset/genetic PD. Two -weeks -old male Line 61 mice and non-transgenic littermates received daily 10 mg/kg montelukast or vehicle orally for 10 weeks. Motor functions were assessed through behavioral tests. Brain tissue was analyzed via unbiased transcriptomics, biochemically, and histologically for various parameters, including microglial and inflammation mediators. Upon montelukast treatment, Line 61 mice significantly improved their beam walk performance compared to vehicle -treated mice. The striatum and cerebellum of the montelukast -treated group showed microglial changes toward a smaller but more ramified appearance. Transcriptomics analysis revealed SGK1, a serine/threonine kinase upstream of NFκB and known target in PD, as the most downregulated gene in the striatum of montelukast -treated animals. This downregulation correlated with reduced striatal protein levels of activated IκB kinase, suggesting a reduced NFκB pathway activity upon montelukast treatment. Thus, oral montelukast administration might be promising for the management of PD, with specific effects on motor coordination and balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.